JP2008534496A - CB1’受容体リガンドとしての新規なテトラヒドロ−1H−ピリド[4,3−b]インドール誘導体 - Google Patents

CB1’受容体リガンドとしての新規なテトラヒドロ−1H−ピリド[4,3−b]インドール誘導体 Download PDF

Info

Publication number
JP2008534496A
JP2008534496A JP2008502944A JP2008502944A JP2008534496A JP 2008534496 A JP2008534496 A JP 2008534496A JP 2008502944 A JP2008502944 A JP 2008502944A JP 2008502944 A JP2008502944 A JP 2008502944A JP 2008534496 A JP2008534496 A JP 2008534496A
Authority
JP
Japan
Prior art keywords
tetrahydro
pyrido
alkyl
indole
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2008502944A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008534496A5 (enExample
Inventor
ユン−シン・チェン
ミロスラウ・トーマシェウスキ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2008534496A publication Critical patent/JP2008534496A/ja
Publication of JP2008534496A5 publication Critical patent/JP2008534496A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
JP2008502944A 2005-03-22 2006-03-17 CB1’受容体リガンドとしての新規なテトラヒドロ−1H−ピリド[4,3−b]インドール誘導体 Abandoned JP2008534496A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0500654 2005-03-22
PCT/SE2006/000339 WO2006101434A1 (en) 2005-03-22 2006-03-17 NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS

Publications (2)

Publication Number Publication Date
JP2008534496A true JP2008534496A (ja) 2008-08-28
JP2008534496A5 JP2008534496A5 (enExample) 2009-04-23

Family

ID=37024033

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008502944A Abandoned JP2008534496A (ja) 2005-03-22 2006-03-17 CB1’受容体リガンドとしての新規なテトラヒドロ−1H−ピリド[4,3−b]インドール誘導体

Country Status (8)

Country Link
US (1) US20100113502A1 (enExample)
EP (1) EP1863810A4 (enExample)
JP (1) JP2008534496A (enExample)
CN (2) CN101175754A (enExample)
AR (1) AR053699A1 (enExample)
TW (1) TW200716628A (enExample)
UY (1) UY29427A1 (enExample)
WO (1) WO2006101434A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510932A (ja) * 2008-01-25 2011-04-07 メディベイション テクノロジーズ, インコーポレイテッド 新規2,3,4,5−テトラヒドロ−1H−ピリド[4,3−b]インドール化合物およびその使用方法
JP2014101389A (ja) * 2008-01-25 2014-06-05 Medivation Technologies Inc 新規2,3,4,5−テトラヒドロ−1H−ピリド[4,3−b]インドール化合物およびその使用方法

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1937263A2 (en) * 2005-10-04 2008-07-02 Medivation, Inc. Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease
EA014906B1 (ru) * 2005-12-01 2011-02-28 Элан Фармасьютикалз, Инк. 5-(арилсульфонил)пиразолопиперидины
WO2008036021A1 (en) * 2006-09-20 2008-03-27 Astrazeneca Ab Tetrahydro-lh-pyrido [3,4 -b] indole derivatives as cbl receptor ligands
WO2008036022A1 (en) * 2006-09-20 2008-03-27 Astrazeneca Ab Tetrahydro-lh-pyrido[3,4-b] indole derivatives as cb1 receptor ligands
RU2329044C1 (ru) * 2006-11-16 2008-07-20 Андрей Александрович Иващенко Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство
US20090062251A1 (en) * 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
CN101868234A (zh) 2007-09-20 2010-10-20 D2E有限公司 具有神经保护和认知增强特性的氢化吡啶并[4,3-b]吲哚的含氟衍生物,其制备方法及应用
ES2552733T3 (es) 2007-11-16 2015-12-01 Rigel Pharmaceuticals, Inc. Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos
US8129390B2 (en) 2007-12-12 2012-03-06 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds and methods for using the same
TWI498328B (zh) * 2008-01-25 2015-09-01 Medivation Technologies Inc 新穎之2,3,4,5-四氫-1h-吡啶并〔4,3-b〕吲哚化合物及其使用方法
BRPI0911681B8 (pt) 2008-04-23 2021-05-25 Rigel Pharmaceuticals Inc composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula in vitro
CN102271508B (zh) 2008-10-31 2015-04-29 梅迪维新技术公司 含有刚性部分的吡啶并[4,3-b]吲哚类化合物
CA2742322A1 (en) 2008-10-31 2010-05-06 Medivation Technologies, Inc. Azepino[4,5-b]indoles and methods of use
US8575186B2 (en) 2009-10-05 2013-11-05 Albany Molecular Research, Inc. Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof
CN102153549B (zh) * 2010-12-14 2012-11-14 华东理工大学 γ咔啉化合物、制备方法和用途
AU2012207335A1 (en) 2011-01-19 2013-07-25 Albany Molecular Research, Inc. Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia
AU2012219251B2 (en) 2011-02-18 2016-05-12 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
CN103864779B (zh) * 2012-12-07 2016-06-22 天津科技大学 一种1-(苯基)-2,3,4,9-四氢-1H-吡啶并[3,4-b]吲哚衍生物的制备及其在抗肿瘤药物中的应用
CN103864781A (zh) * 2012-12-13 2014-06-18 天津科技大学 一种新型1,9-二取代四氢咔啉类衍生物的制备及其抗肿瘤药物中的应用
BR112015029455A8 (pt) * 2013-05-28 2020-03-17 Astrazeneca Ab compostos químicos, uso, métodos e composições para prevenção ou tratamento de câncer
DK3433256T3 (da) 2016-10-24 2019-10-28 Astrazeneca 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinolinderivat, der er anvendeligt til behandling af cancer
ES2766249T3 (es) 2017-01-30 2020-06-12 Astrazeneca Ab Moduladores del receptor de estrógeno
KR20230005270A (ko) 2020-04-24 2023-01-09 아스트라제네카 아베 약학적 제형
IL297216A (en) 2020-04-24 2022-12-01 Astrazeneca Ab Dosage regimen for the treatment of cancer
CN116425670A (zh) * 2022-07-15 2023-07-14 英矽智能科技(上海)有限公司 作为tead抑制剂的新型杂环化合物
KR20240141133A (ko) * 2023-03-15 2024-09-25 한국과학기술연구원 신규한 피리도인돌 유도체 화합물을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US62251A (en) * 1867-02-19 Improvement in machines foe burnishing plated ware
JPH0256485A (ja) * 1988-04-27 1990-02-26 Glaxo Group Ltd ラクタム誘導体
US5008272A (en) * 1988-08-15 1991-04-16 Glaxo Group Limited Lactam derivatives
US6448257B1 (en) * 1998-05-22 2002-09-10 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
EP1254115A2 (en) * 2000-02-11 2002-11-06 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
CO5300399A1 (es) * 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
US7534897B2 (en) * 2002-05-16 2009-05-19 Shionogi & Co., Ltd. Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
JP2005162657A (ja) * 2003-12-02 2005-06-23 Takeda Chem Ind Ltd カンナビノイド受容体調節剤
WO2008036022A1 (en) * 2006-09-20 2008-03-27 Astrazeneca Ab Tetrahydro-lh-pyrido[3,4-b] indole derivatives as cb1 receptor ligands
WO2008036021A1 (en) * 2006-09-20 2008-03-27 Astrazeneca Ab Tetrahydro-lh-pyrido [3,4 -b] indole derivatives as cbl receptor ligands

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510932A (ja) * 2008-01-25 2011-04-07 メディベイション テクノロジーズ, インコーポレイテッド 新規2,3,4,5−テトラヒドロ−1H−ピリド[4,3−b]インドール化合物およびその使用方法
JP2014101389A (ja) * 2008-01-25 2014-06-05 Medivation Technologies Inc 新規2,3,4,5−テトラヒドロ−1H−ピリド[4,3−b]インドール化合物およびその使用方法
US9115137B2 (en) 2008-01-25 2015-08-25 Medivation Technologies, Inc. 2,3,4,5-tetrahydro-1H-pyrido[4,3-B]indole compounds and methods of use thereof

Also Published As

Publication number Publication date
CN101175754A (zh) 2008-05-07
AR053699A1 (es) 2007-05-16
WO2006101434A1 (en) 2006-09-28
EP1863810A4 (en) 2010-03-31
TW200716628A (en) 2007-05-01
CN102030750A (zh) 2011-04-27
UY29427A1 (es) 2006-10-31
EP1863810A1 (en) 2007-12-12
US20100113502A1 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
JP2008534496A (ja) CB1’受容体リガンドとしての新規なテトラヒドロ−1H−ピリド[4,3−b]インドール誘導体
EP2953940B1 (en) Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic m4 receptor agonists
US20090062251A1 (en) Novel Compounds 002
AU2007244002A1 (en) Compounds that are agonists of muscarinic receptors and that may be effective in treating pain, Alzheimer's disease and/or Schizophrenia
CN117616030A (zh) 食欲素受体激动剂及其用途
JP6173431B2 (ja) モルヒナン誘導体
SA07280303B1 (ar) مشتقات بها استبدال من (3as, 7as)-1-3A,4,5,6,7-Hexahydro-3H-Benzoimidazol-2-One والعمليات الخاصة بتحضيرها، والتركيبات المحتوية عليها والتطبيقات
CN114828963A (zh) 作为Kv1.3钾SHAKER通道阻滞剂的芳基杂二环化合物
WO2008100621A2 (en) Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s
WO2008100618A2 (en) Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s
AU2012323038B2 (en) 2-oxo-piperidinyl derivatives
WO2020085234A1 (ja) モルヒナン誘導体
WO2008036021A1 (en) Tetrahydro-lh-pyrido [3,4 -b] indole derivatives as cbl receptor ligands
JP2023545065A (ja) オートタキシン抑制剤化合物
AU2005287429A1 (en) Compounds, compositions containing them, preparations thereof and uses thereof II
EP4543446A1 (en) Substituted fused bicyclic compounds and related methods of treatment
JP7678756B2 (ja) アゼパン誘導体
JP2013523806A (ja) スルタム化合物
JP2023015414A (ja) エポキシアゼパン誘導体
WO2008036022A1 (en) Tetrahydro-lh-pyrido[3,4-b] indole derivatives as cb1 receptor ligands
JP2013518094A (ja) γ−セクレターゼモジュレーターとしてのアミノシクロヘキサンおよびアミノテトラヒドロピランならびに関連化合物
MXPA06008941A (en) Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof
KR20070057856A (ko) 화합물, 그를 함유하는 조성물, 그의 제조 방법 및 그의용도
MX2007003121A (es) Derivados de bencimidazol, compuestos, composiciones que los contienen, preparacion y usos de los mismos ii.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090303

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20090424